Journal of translational medicine

How the RNA-modifying enzyme ALKBH5 may influence cancer treatment

Updated

Abstract

m6A RNA methylation is the most prevalent epitranscriptomic modification affecting various RNA types.

  • m6A is a dynamic and reversible modification present in mRNA, rRNA, miRNA, lncRNA, circRNA, and snRNA.
  • is an m6A demethylase associated with tumorigenesis and progression by influencing RNA metabolism and gene expression.
  • Aberrant expression of ALKBH5 is frequently observed in multiple cancers, where it may promote tumor initiation and accelerate cancer cell proliferation.
  • ALKBH5 could impact therapeutic responses in various malignancies, but its role in therapy responsiveness and drug resistance is not well understood.
  • The review evaluates ALKBH5-mediated regulatory pathways in relation to chemotherapy, radiotherapy, and immunotherapy.

Simplified

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Declarations. Ethics approval and consent to participate: This is not applicable for this review. Competing interests: The authors declare no competing interests. Clinical trial number: Not applicable.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free